Business Context and Reporting Period
Company: HALOZYME THERAPEUTICS, INC.
Filing Type: Form 8-K (Current Report)
Date: December 16, 2005
Event: Closure of a previously announced registered direct offering of common stock.
Key Financial Metrics
This filing reports on a specific capital raising event rather than periodic operating results. Key figures include:
- Shares Issued: 10,000,000 shares of common stock.
- Offering Price: $1.75 per share.
- Gross Proceeds: Approximately $17.5 million.
- Net Proceeds: Approximately $16.1 million (after placement agent fees and estimated offering expenses).
- Operating Metrics: Revenue, profit, cash flow, margins, and debt levels are not reported in this filing.
Material Changes
The primary material change is the increase in the company's cash liquidity resulting from the equity offering. The filing does not provide comparative data against prior periods for operating performance.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the successful closing of the offering to certain institutional investors.
Guidance and Risks: No forward-looking guidance, risk factors, or discussion of contingencies is included in this specific 8-K report.
Investor Verification Checklist
- Verify the final use of the $16.1 million in net proceeds in subsequent filings (e.g., 10-K or 10-Q).
- Confirm the dilution impact of the 10,000,000 new shares on existing shareholders.
- Review the specific terms of the placement agent fees deducted from the gross proceeds.